 | • レポートコード：MRC309Z7764 • 出版社/出版日：GlobalInfoResearch / 2023年9月 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| GlobalInfoResearchの最新の調査によると、世界のアダリムマブモノクローナル抗体バイオシミラーの市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。 このレポートは、世界のアダリムマブモノクローナル抗体バイオシミラー市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。 市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。 本レポートの主な目的は次のとおりです。 - 世界および主要国の市場機会の規模を決定するため - アダリムマブモノクローナル抗体バイオシミラーの成長可能性を評価するため - 各製品および最終用途市場の将来の成長を予測するため - 市場に影響を与える競争要因を評価するため アダリムマブモノクローナル抗体バイオシミラー市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 種類別セグメント ・シリンジ、ペン 用途別セグメント ・強直性脊椎炎、関節リウマチ、クローン病、その他 主要な市場プレーヤー ・Cadila Healthcare、Torrent Pharmaceuticals、Amgen、Boehringer Ingelheim、Novartis、Samsung Bioepis、Viatris、Pfizer、Fresenius Kabi、Coherus 地域別セグメントは次の地域・国をカバーします。 ・北米（米国、カナダ、メキシコ） ・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南アメリカ（ブラジル、アルゼンチン、コロンビア） ・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ） 本調査レポートの内容は計15章あります。 ・第1章では、アダリムマブモノクローナル抗体バイオシミラー製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。 ・第2章では、主要なアダリムマブモノクローナル抗体バイオシミラーメーカーの企業概要、2019年～2022年までのアダリムマブモノクローナル抗体バイオシミラーの価格、販売量、売上、市場シェアを掲載しています。 ・第3章では、主要なアダリムマブモノクローナル抗体バイオシミラーメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。 ・第4章では、2018年～2029年までの地域別アダリムマブモノクローナル抗体バイオシミラーの販売量、売上、成長性を示しています。 ・第5、6章では、2018年～2029年までのアダリムマブモノクローナル抗体バイオシミラーの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。 ・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域でのアダリムマブモノクローナル抗体バイオシミラー市場予測を収録しています。 ・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。 ・第13章では、主要な原材料、主要なサプライヤー、およびアダリムマブモノクローナル抗体バイオシミラーの産業チェーンを掲載しています。 ・第14、15章では、アダリムマブモノクローナル抗体バイオシミラーの販売チャネル、販売業者、顧客、調査結果について説明します。 ***** 目次(一部) ***** ・市場概要 - アダリムマブモノクローナル抗体バイオシミラーの概要 - 種類別分析（2018年vs2022年vs2029年）：シリンジ、ペン - 用途別分析（2018年vs2022年vs2029年）：強直性脊椎炎、関節リウマチ、クローン病、その他 - 世界のアダリムマブモノクローナル抗体バイオシミラー市場規模・予測 - 世界のアダリムマブモノクローナル抗体バイオシミラー生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Cadila Healthcare、Torrent Pharmaceuticals、Amgen、Boehringer Ingelheim、Novartis、Samsung Bioepis、Viatris、Pfizer、Fresenius Kabi、Coherus ・メーカー別市場シェア・市場集中度 ・地域別市場分析2018年-2029年 ・種類別分析2018年-2029年：シリンジ、ペン ・用途別分析2018年-2029年：強直性脊椎炎、関節リウマチ、クローン病、その他 ・アダリムマブモノクローナル抗体バイオシミラーの北米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・アダリムマブモノクローナル抗体バイオシミラーのヨーロッパ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・アダリムマブモノクローナル抗体バイオシミラーのアジア市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・アダリムマブモノクローナル抗体バイオシミラーの南米市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・アダリムマブモノクローナル抗体バイオシミラーの中東・アフリカ市場 - 種類別市場規模2018年-2029年 - 用途別市場規模2018年-2029年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析） ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
According to our (Global Info Research) latest study, the global Adalimumab Monoclonal Antibody Biosimilar market size was valued at USD 433.2 million in 2022 and is forecast to a readjusted size of USD 955.4 million by 2029 with a CAGR of 12.0% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars provides an alternative option for healthcare providers and payers to choose from, potentially reducing the overall healthcare expenditure associated with biologic treatments.
Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.
This report is a detailed and comprehensive analysis for global Adalimumab Monoclonal Antibody Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Adalimumab Monoclonal Antibody Biosimilar market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab Monoclonal Antibody Biosimilar market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab Monoclonal Antibody Biosimilar market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Adalimumab Monoclonal Antibody Biosimilar market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Adalimumab Monoclonal Antibody Biosimilar
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Adalimumab Monoclonal Antibody Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cadila Healthcare, Torrent Pharmaceuticals, Amgen, Boehringer Ingelheim and Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Adalimumab Monoclonal Antibody Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Syringe
Pen
Market segment by Application
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Major players covered
Cadila Healthcare
Torrent Pharmaceuticals
Amgen
Boehringer Ingelheim
Novartis
Samsung Bioepis
Viatris
Pfizer
Fresenius Kabi
Coherus
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Adalimumab Monoclonal Antibody Biosimilar product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Adalimumab Monoclonal Antibody Biosimilar, with price, sales, revenue and global market share of Adalimumab Monoclonal Antibody Biosimilar from 2018 to 2023.
Chapter 3, the Adalimumab Monoclonal Antibody Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Adalimumab Monoclonal Antibody Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Adalimumab Monoclonal Antibody Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Adalimumab Monoclonal Antibody Biosimilar.
Chapter 14 and 15, to describe Adalimumab Monoclonal Antibody Biosimilar sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Adalimumab Monoclonal Antibody Biosimilar
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Syringe
1.3.3 Pen
1.4 Market Analysis by Application
1.4.1 Overview: Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Ankylosing Spondylitis
1.4.3 Rheumatoid Arthritis
1.4.4 Crohn’s Disease
1.4.5 Other
1.5 Global Adalimumab Monoclonal Antibody Biosimilar Market Size & Forecast
1.5.1 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity (2018-2029)
1.5.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Cadila Healthcare
2.1.1 Cadila Healthcare Details
2.1.2 Cadila Healthcare Major Business
2.1.3 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.1.4 Cadila Healthcare Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Cadila Healthcare Recent Developments/Updates
2.2 Torrent Pharmaceuticals
2.2.1 Torrent Pharmaceuticals Details
2.2.2 Torrent Pharmaceuticals Major Business
2.2.3 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.2.4 Torrent Pharmaceuticals Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Torrent Pharmaceuticals Recent Developments/Updates
2.3 Amgen
2.3.1 Amgen Details
2.3.2 Amgen Major Business
2.3.3 Amgen Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.3.4 Amgen Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Amgen Recent Developments/Updates
2.4 Boehringer Ingelheim
2.4.1 Boehringer Ingelheim Details
2.4.2 Boehringer Ingelheim Major Business
2.4.3 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.4.4 Boehringer Ingelheim Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Boehringer Ingelheim Recent Developments/Updates
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.5.4 Novartis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Novartis Recent Developments/Updates
2.6 Samsung Bioepis
2.6.1 Samsung Bioepis Details
2.6.2 Samsung Bioepis Major Business
2.6.3 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.6.4 Samsung Bioepis Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Samsung Bioepis Recent Developments/Updates
2.7 Viatris
2.7.1 Viatris Details
2.7.2 Viatris Major Business
2.7.3 Viatris Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.7.4 Viatris Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Viatris Recent Developments/Updates
2.8 Pfizer
2.8.1 Pfizer Details
2.8.2 Pfizer Major Business
2.8.3 Pfizer Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.8.4 Pfizer Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Pfizer Recent Developments/Updates
2.9 Fresenius Kabi
2.9.1 Fresenius Kabi Details
2.9.2 Fresenius Kabi Major Business
2.9.3 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.9.4 Fresenius Kabi Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Fresenius Kabi Recent Developments/Updates
2.10 Coherus
2.10.1 Coherus Details
2.10.2 Coherus Major Business
2.10.3 Coherus Adalimumab Monoclonal Antibody Biosimilar Product and Services
2.10.4 Coherus Adalimumab Monoclonal Antibody Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Coherus Recent Developments/Updates
3 Competitive Environment: Adalimumab Monoclonal Antibody Biosimilar by Manufacturer
3.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Manufacturer (2018-2023)
3.2 Global Adalimumab Monoclonal Antibody Biosimilar Revenue by Manufacturer (2018-2023)
3.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Adalimumab Monoclonal Antibody Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Adalimumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
3.4.2 Top 6 Adalimumab Monoclonal Antibody Biosimilar Manufacturer Market Share in 2022
3.5 Adalimumab Monoclonal Antibody Biosimilar Market: Overall Company Footprint Analysis
3.5.1 Adalimumab Monoclonal Antibody Biosimilar Market: Region Footprint
3.5.2 Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Type Footprint
3.5.3 Adalimumab Monoclonal Antibody Biosimilar Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Adalimumab Monoclonal Antibody Biosimilar Market Size by Region
4.1.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
4.1.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
4.1.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Region (2018-2029)
4.2 North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.3 Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.4 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.5 South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
4.6 Middle East and Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
5.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Type (2018-2029)
5.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
6.2 Global Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Application (2018-2029)
6.3 Global Adalimumab Monoclonal Antibody Biosimilar Average Price by Application (2018-2029)
7 North America
7.1 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
7.2 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
7.3 North America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
7.3.1 North America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
7.3.2 North America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
8.2 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
8.3 Europe Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
8.3.1 Europe Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
8.3.2 Europe Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Market Size by Region
9.3.1 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
10.2 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
10.3 South America Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
10.3.1 South America Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
10.3.2 South America Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Market Size by Country
11.3.1 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Adalimumab Monoclonal Antibody Biosimilar Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Adalimumab Monoclonal Antibody Biosimilar Market Drivers
12.2 Adalimumab Monoclonal Antibody Biosimilar Market Restraints
12.3 Adalimumab Monoclonal Antibody Biosimilar Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Adalimumab Monoclonal Antibody Biosimilar and Key Manufacturers
13.2 Manufacturing Costs Percentage of Adalimumab Monoclonal Antibody Biosimilar
13.3 Adalimumab Monoclonal Antibody Biosimilar Production Process
13.4 Adalimumab Monoclonal Antibody Biosimilar Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Adalimumab Monoclonal Antibody Biosimilar Typical Distributors
14.3 Adalimumab Monoclonal Antibody Biosimilar Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer